Tumour GDF-15 Expression and Clinical Outcomes in Intermediate-Risk Metastatic Clear-Cell Renal Cell Carcinoma Treated with Second-Line Nivolumab
- DOI
- 10.3390/curroncol33090531
- Published
- 09
- Container
- Current Oncology
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- supportingDirectory of Open Access Journals: A matching record was returned by DOAJ.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.3390/curroncol33090531,
title = {Tumour GDF-15 Expression and Clinical Outcomes in Intermediate-Risk Metastatic Clear-Cell Renal Cell Carcinoma Treated with Second-Line Nivolumab},
author = {Orhun Akdogan and Betul Ogut and Osman Sutcuoglu and Melike Urganci and Burcu Ulas Kahya and Ipek Isik Gonul and Hatice Azra Begum Salimoglu and Tuba Ugur Tuzcu and Ozan Yazici and Ahmet Ozet and Nuriye Ozdemir},
year = {2026},
journal = {Current Oncology},
doi = {10.3390/curroncol33090531},
url = {https://doi.org/10.3390/curroncol33090531}
}RIS
TY - JOUR TI - Tumour GDF-15 Expression and Clinical Outcomes in Intermediate-Risk Metastatic Clear-Cell Renal Cell Carcinoma Treated with Second-Line Nivolumab AU - Orhun Akdogan AU - Betul Ogut AU - Osman Sutcuoglu AU - Melike Urganci AU - Burcu Ulas Kahya AU - Ipek Isik Gonul AU - Hatice Azra Begum Salimoglu AU - Tuba Ugur Tuzcu AU - Ozan Yazici AU - Ahmet Ozet AU - Nuriye Ozdemir PY - 2026 JO - Current Oncology DO - 10.3390/curroncol33090531 UR - https://doi.org/10.3390/curroncol33090531 ER -
APA
Akdogan, O., Ogut, B., Sutcuoglu, O., Urganci, M., Kahya, B. U., Gonul, I. I., Salimoglu, H. A. B., Tuzcu, T. U., Yazici, O., Ozet, A., & Ozdemir, N. (2026). Tumour GDF-15 Expression and Clinical Outcomes in Intermediate-Risk Metastatic Clear-Cell Renal Cell Carcinoma Treated with Second-Line Nivolumab. Current Oncology. https://doi.org/10.3390/curroncol33090531
Source records
- doaj · retrieved 2026-09-25T21:00:37.303Z